Popular Stories

PRTK Tag

  • All
  • Biotechnology
  • Cannabis
  • Education
  • Energy
  • Investing Ideas
  • Macro
  • Miscellaneous
  • Sectors
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Paratek withdraws European Marketing Authorization for Nuzyra

Paratek Pharmaceuticals (NASDAQ: PRTK), a commercial-stage biopharmaceutical Company, announced the withdrawal of its submission to the European Medicines Agency (EMA), for the grant of Marketing Authorization Application (MAA) for NUZYRA® (omadacycline). The Company was developing the candidate for two indications namely, acute bacterial skin and...

A paradigm shift in the ACNE treatment industry?

Acne is one of the most common skin disorders in the U.S affecting over 50 million people annually. An estimated 85% of young adults aged between 12-25 years suffer from it according to the Global Burden of Disease (GDB) study. The rise in androgen levels during puberty,...

WordPress Video Lightbox Plugin